Archive | Enrolled Participants News RSS feed for this section

The Michael J. Fox Foundation Announces $25,000 PPMI Data Challenge to Advance Parkinson’s Understanding and Study Design

Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson’s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: • What factors at baseline predict […]

Continue reading...

2016 PPMI Annual Meeting held in New York City

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]

Continue reading...

PPMI Q1 2016 Study Update call

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.

Continue reading...

Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of ?-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.

Continue reading...

Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid ?-synuclein species as surrogate biomarkers for Parkinson’s disease

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF ?-synuclein species as surrogate biomarkers for Parkinson’s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]

Continue reading...

Dr. Martin Rabey to use PPMI biospecimens for validation of a blood based gene expression assay

A critical component of PPMI is the standardized, longitudinal collection of biospecimens. Each month the Biospecimen Review Committee examines requests for biospecimens collected through the PPMI study. We are excited to announce approval for Dr. Martin Rabey, the Chief Medical Officer of BioShai Ltd, for a project entitled: Validation of a blood based gene expression […]

Continue reading...

Update to PPMI Protocol

PPMI’s updated study protocol (version 11.0) allows for subjects enrolled in the Parkinson’s Disease (PD) and Healthy Control cohorts to continue participation in PPMI beyond month 60.  Subjects in these two cohorts consenting to amendment 10 will be followed through month 96 (V15). Subjects in the PD cohort will continue with annual in person visits […]

Continue reading...

Diffusion Tensor Imaging Reflects Degree of Motor Symptoms

In a recent publication in Movement Disorders, Zhang, et al. used PPMI data and found that diffusion tensor imaging (DTI) detected neural fiber abnormalities in people with Parkinson's disease (PD) and that the degree of deviation from normal neural fiber integrity is associated with the severity of motor symptoms in patients.

Continue reading...

PPMI Participating in Upcoming Datathon

The tranSMART Foundation is hosting the Cross Neurodegenerative Diseases Datathon June 30 - July 2. Scientists will use the tranSMART Platform to perform analyses across multiple public datasets in the neurodegenerative disease field, including PPMI, BioFIND, LRRK2, ADNI, and GEO PD.

Continue reading...

Biospecimen Analysis Call for Participants Posted

Dr. Mollenhauer: "[Cerebrospinal fluid] bears the possibility to reflect the underlying biology of the disease process." Find out what makes the PPMI biospecimens, like cerebrospinal fluid, so important to finding progression markers for PD.

Continue reading...